MedTrace Logo

Esmolol vs. Labetalol in Endoscopic Sinus Surgery

NCT03661346 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2021-02-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare esmolol and labetalol bleeding and intra-operative visibility scores in functional endoscopic sinus surgery.

Conditions

  • Chronic Sinusitis

Interventions

DRUG

Labetalol

Aliquots of 20mg of Labetol • Maximum Dose - 300mg total for case

DRUG

Esmolol

Infusion - 0.1mg/kg/min • Maximum Dose - after 30 minutes, 0.3mg/kg/min

Sponsors & Collaborators

  • The University of Texas Medical Branch, Galveston

    lead OTHER

Principal Investigators

  • Mohamad Chaaban, MD · University of Texas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2018-03-30
Completion
2018-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03661346 on ClinicalTrials.gov